NASDAQ:KMDA - Kamada Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.33 +0.04 (+0.76 %) (As of 01/22/2019 01:13 AM ET)Previous Close$5.29Today's Range$5.33 - $5.3652-Week Range$4.35 - $6.45Volume3,414 shsAverage Volume8,415 shsMarket Capitalization$214.60 millionP/E Ratio29.61Dividend YieldN/ABeta1.16 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD). It also provides immunoglobulin products that comprise KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company offers other products, including Heparin Lock Flush to maintain patency of indwelling IV catheter; Kamacaine 0.5% used as anesthesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; and Human Transferrin, which is used as a cultural medium for diagnostic assays and cell cultures. Further, the company distributes respiratory products, including Bramitob to manage chronic pulmonary infection and FOSTER for the treatment of asthma; and immunoglobulins comprising IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for prevention of hepatitis B virus; and Megalotect, a CMV immunoglobulin. Additionally, it provides Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of blood plasma. Kamada Ltd. also offers coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Baxter International Inc.; Chiesi Farmaceutici; PARI GmbH; and Kedrion S.p.A. The company was founded in 1990 and is headquartered in Rehovot, Israel. Receive KMDA News and Ratings via Email Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KMDA Previous Symbol CUSIPN/A Webwww.kamada.com Phone972-8940-6472Debt Debt-to-Equity Ratio0.01 Current Ratio4.86 Quick Ratio3.31Price-To-Earnings Trailing P/E Ratio29.61 Forward P/E Ratio18.38 P/E GrowthN/A Sales & Book Value Annual Sales$102.82 million Price / Sales2.09 Cash Flow$0.2584 per share Price / Cash Flow20.63 Book Value$2.22 per share Price / Book2.40Profitability EPS (Most Recent Fiscal Year)$0.18 Net Income$6.90 million Net Margins10.60% Return on Equity11.70% Return on Assets8.98%Miscellaneous Employees413 Outstanding Shares40,260,000Market Cap$214.60 million OptionableNot Optionable Kamada (NASDAQ:KMDA) Frequently Asked Questions What is Kamada's stock symbol? Kamada trades on the NASDAQ under the ticker symbol "KMDA." How were Kamada's earnings last quarter? Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings data on Monday, November, 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.05. The biotechnology company earned $14.98 million during the quarter, compared to analysts' expectations of $25.99 million. Kamada had a return on equity of 11.70% and a net margin of 10.60%. View Kamada's Earnings History. When is Kamada's next earnings date? Kamada is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Kamada. What guidance has Kamada issued on next quarter's earnings? Kamada updated its FY 2018 earnings guidance on Monday, November, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $102-108 million, compared to the consensus revenue estimate of $111.59 million.Kamada also updated its FY 2019 guidance to EPS. What price target have analysts set for KMDA? 2 equities research analysts have issued 1-year price targets for Kamada's shares. Their predictions range from $7.00 to $11.00. On average, they anticipate Kamada's share price to reach $9.00 in the next year. This suggests a possible upside of 68.9% from the stock's current price. View Analyst Price Targets for Kamada. What is the consensus analysts' recommendation for Kamada? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kamada. Has Kamada been receiving favorable news coverage? News headlines about KMDA stock have trended very positive this week, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kamada earned a news sentiment score of 3.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. Who are some of Kamada's key competitors? Some companies that are related to Kamada include Homology Medicines (FIXX), Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Athenex (ATNX), Radius Health (RDUS), Y-mAbs Therapeutics (YMAB), Principia Biopharma (PRNB), ImmunoGen (IMGN), Epizyme (EPZM), Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX), G1 Therapeutics (GTHX), AC Immune (ACIU), Urogen Pharma (URGN) and Rocket Pharmaceuticals (RCKT). Who are Kamada's key executives? Kamada's management team includes the folowing people: Mr. Amir London, Chief Exec. Officer (Age 50)Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 68)Mr. Eran Nir, VP of Operations & Plant Mang. (Age 46)Dr. Naveh Tov M.D., Ph.D., VP of Clinical Devel. & Medical Director for Pulmonary Diseases (Age 55)Mr. Chaime Orlev, Chief Financial Officer (Age 49) How do I buy shares of Kamada? Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Kamada's stock price today? One share of KMDA stock can currently be purchased for approximately $5.33. How big of a company is Kamada? Kamada has a market capitalization of $214.60 million and generates $102.82 million in revenue each year. The biotechnology company earns $6.90 million in net income (profit) each year or $0.18 on an earnings per share basis. Kamada employs 413 workers across the globe. What is Kamada's official website? The official website for Kamada is http://www.kamada.com. How can I contact Kamada? Kamada's mailing address is 2 HOLTZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected] MarketBeat Community Rating for Kamada (NASDAQ KMDA)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 168 (Vote Outperform)Underperform Votes: 200 (Vote Underperform)Total Votes: 368MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/22/2019 by MarketBeat.com StaffFeatured Article: What is a balanced fund?